PD184352 (CI-1040)
mRNA synthesis
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
SYBR Safe DNA Gel Stain
Safe and sensitive stain for visualization of DNA or RNA in agarose or acrylamide gels.
Inhibitor Cocktails
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
PD184352 (also known as CI-1040), a benzhydroxamate derivative, is a potent and highly selective MEK1/2, two members of the family of MAPKKs, inhibitor that inhibits purified MEK1 with IC50 of 17 nM in a non-ATP and non-ERK1/2 competitive manner [1].
PD184352 binds to a hydrophobic pocket, which is located in a region with low sequence homology to other kinases, adjacent to the Mg-ATP binding site of MEK1 and MEK2 inducing a conformational change in un-phosphorylated MEK1/2 and hence inactivating the un-phosphorylated MEK1/2 [1].
PD184352 has been found to be actively against tumors, where it inhibits the growth of colon carcinomas in mouse xenograft models [1].
References:
[1] Frémin C, Meloche S. From basic research to clinical development of MEK1/2 inhibitors for cancer therapy. J Hematol Oncol. 2010 Feb 11;3:8. doi: 10.1186/1756-8722-3-8.
| Physical Appearance | A solid |
| Storage | Store at -20°C |
| M.Wt | 478.67 |
| Cas No. | 212631-79-3 |
| Formula | C17H14ClF2IN2O2 |
| Solubility | ≥47.9mg/mL in DMSO |
| Chemical Name | 2-(2-chloro-4-iodoanilino)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide |
| SDF | Download SDF |
| Canonical SMILES | C1CC1CONC(=O)C2=C(C(=C(C=C2)F)F)NC3=C(C=C(C=C3)I)Cl |
| Shipping Condition | Evaluation sample solution: ship with blue ice. All other available sizes: ship with RT, or blue ice upon request. |
| General tips | For obtaining a higher solubility, please warm the tube at 37°C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months. |
| Cell experiment: [1] | |
|
Cell lines |
CCl39 cells expressing FLAG-ERK5 |
|
Preparation method |
The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months. |
|
Reaction Conditions |
IC50: < 1 μM, 90 min |
|
Applications |
Cells were serum-starved for 16 h prior to the addition of PD184352, or an equivalent of DMSO vehicle control for 90 min. Single dishes of cells were then stimulated with 10% FBS for 15 min and immune-complex kinase assays performed with either myelin basic protein (MBP; ERK1) or GST-MEF2C (ERK5), as a substrate. PD184352 inhibited FBS-induced ERK1 activation with an IC50 below 1 μM, whereas even a dose of 20 μM PD184352 was insufficient to inhibit ERK5 activity, induced in the same manner and assayed from the same cell extracts as ERK1. |
| Animal experiment: [2] | |
|
Animal models |
DBA/2-pcy/pcy mice |
|
Dosage form |
Oral administration, 400 mg/kg daily for the first week and then every third day for 6 additional weeks |
|
Applications |
The body weight of the PD184352-treated pcy mice was slightly but significantly lower than that of the control pcy mice. The kidney weight, kidney weight to body weight ratio, BP, and serum creatinine levels of the PD184352-treated pcy mice also were significantly less at the end of treatment. Water intake of PD184352-treated pcy mice was reduced, and urine osmolality was increased. The cystic index also was significantly lower in the PD184352-treated pcy mice than in the control pcy mice. |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: [1] SQUIRES M, NIXON P, COOK S. Cell-cycle arrest by PD184352 requires inhibition of extracellular signal-regulated kinases (ERK) 1/2 but not ERK5/BMK1. Biochem. J, 2002, 366: 673-680. [2] Omori S, Hida M, Fujita H, et al. Extracellular signal–regulated kinase inhibition slows disease progression in mice with polycystic kidney disease. Journal of the American Society of Nephrology, 2006, 17(6): 1604-1614. |
|
| Description | PD184352 is a selective inhibitor of MEK with Ki value of 300 nM. | |||||
| Targets | MEK | |||||
| IC50 | 300 nM (Ki) | |||||
Quality Control & MSDS
- View current batch:
Chemical structure
